Description

MK-677 Capsules 15MG

We provide MK-677 Capsules as a capsule-format research product containing 15MG of ibutamoren per capsule, 120 capsules per container, and a stated 99.1% purity. Furthermore, ibutamoren, also known as MK-677 or MK-0677, is an orally bioavailable, non-peptide small-molecule growth hormone secretagogue that acts through the growth hormone secretagogue receptor (GHS-R). Consequently, researchers have investigated its relationship with pulsatile growth hormone release, the IGF-1 axis, endocrine signaling, and metabolic physiology.

Key Attributes

• Brand: AvigenLab
• Product Name: MK-677 Capsules
• Active Compound: Ibutamoren
• Amount Per Capsule: 15MG
• Capsule Count: 120 Capsules
• Total Labeled Quantity: 1,800MG
• Stated Purity: 99.1%
• Molecular Type: Small-Molecule Non-Peptide
• Molecular Formula: C₂₈H₄₀N₄O₈S₂*
• Molecular Weight: 624.8 g/mol*
• CAS Number: 159752-10-0*
• Product Format: Capsules
• Classification: Research Use Only
• Human Use: Not For Human Use

*The formula, molecular weight, and CAS number above correspond to ibutamoren mesylate, the MK-677 salt form documented by PubChem.

MK-677 Capsules Product Overview

We provide MK-677 Capsules for research involving growth hormone secretagogue signaling, pituitary hormone release, IGF-1 regulation, endocrine physiology, and metabolic research. Moreover, published studies have demonstrated that MK-677 can enhance pulsatile growth hormone secretion and increase circulating IGF-1 concentrations under experimental conditions.

Additionally, ibutamoren interacts with GHS-R, a receptor involved in regulating pulsatile growth hormone release. Therefore, researchers can examine the compound within experimental models designed to investigate receptor activation, endocrine signaling, and downstream growth-factor responses.

Explore additional research materials through our Online Store.

MK-677 Capsules Product Identification

We identify MK-677 Capsules through their active ibutamoren content, 15MG-per-capsule configuration, 120-capsule quantity, and stated 99.1% purity. Furthermore, PubChem identifies ibutamoren as a small-molecule, non-peptide growth hormone secretagogue and distinguishes ibutamoren mesylate as its mesylate salt form.

Accordingly, the product name, active compound, capsule quantity, amount per capsule, purity designation, molecular identity, and Research Use Only classification provide clear reference points for laboratory documentation and inventory management.

Product Category

We classify MK-677 Capsules within our research compound collection for endocrine, growth-factor, metabolic, and receptor-signaling investigations. Accordingly, the product provides researchers with a defined small-molecule material rather than a peptide-based growth-factor product.

Moreover, research has examined MK-677 across several physiological systems. Studies have investigated growth hormone secretion, IGF-1 responses, IGF-binding protein-3, bone turnover markers, body composition, and metabolic parameters. Consequently, the compound has developed a broad experimental profile within endocrinology and metabolic research.

Scientific Characteristics

We characterize MK-677 Capsules through ibutamoren, a non-peptide small molecule that acts as a growth hormone secretagogue. In particular, PubChem lists ibutamoren free base with the molecular formula C₂₇H₃₆N₄O₅S and molecular weight of 528.7 g/mol, while the mesylate salt form carries a molecular weight of 624.8 g/mol and the formula C₂₈H₄₀N₄O₈S₂.

Furthermore, research characterizes GHS-R as a receptor through which synthetic secretagogues such as MK-0677 can amplify pulsatile growth hormone release. Meanwhile, studies have demonstrated corresponding increases in circulating IGF-1 under various experimental conditions.

Research Applications

We position MK-677 Capsules for research involving growth hormone secretagogue signaling, GHS-R activity, pulsatile growth hormone release, IGF-1 regulation, IGFBP-3 responses, endocrine physiology, bone metabolism, and metabolic research.

Additionally, controlled research in healthy older adults found that MK-677 increased mean 24-hour growth hormone concentrations and serum IGF-1 while enhancing existing pulsatile GH secretion. Consequently, researchers have used the compound to investigate age-related changes within the GH/IGF-1 axis.

Likewise, research involving obese adults reported sustained increases in GH, IGF-1, and IGFBP-3 during experimental treatment, alongside changes in fat-free mass. Nevertheless, that study also reported impaired glucose homeostasis during oral glucose-tolerance testing, demonstrating why researchers should evaluate endocrine and metabolic findings together rather than focusing on a single endpoint.

Product Configuration

We provide MK-677 Capsules in a container holding 120 capsules, with each capsule labeled at 15MG. Accordingly, the full container represents a total labeled quantity of 1,800MG.

Furthermore, the capsule configuration distinguishes this presentation from injectable peptides, spray products, and other research compounds within our collection. Therefore, researchers can identify the material through its specific capsule format, quantity, active compound, and product labeling.

Product Features

The primary features include 15MG per capsule, 120 capsules, 1,800MG total labeled quantity, 99.1% stated purity, and an ibutamoren-based small-molecule composition. Additionally, our product presentation identifies the material as Research Use Only and Not For Human Use.

Moreover, research has established that MK-677 can interact with GHS-R and influence the GH/IGF-1 axis. Studies have also examined its effects on bone-turnover markers and body-composition parameters. Consequently, the material provides researchers with a defined compound for investigating interconnected endocrine and metabolic pathways.

Product Specifications

The starred molecular specifications correspond to ibutamoren mesylate, which PubChem identifies as the MK-677 mesylate salt form.

Intended Research Context

We identify the material as Research Use Only and Not For Human Use. Accordingly, our documentation focuses on laboratory research rather than therapeutic or consumer applications.

In particular, researchers can examine the compound within experimental systems involving GHS-R signaling, pituitary growth hormone release, IGF-1 regulation, endocrine feedback, bone turnover, and metabolic physiology. Furthermore, published human research has investigated these pathways under controlled experimental conditions, providing a substantial scientific basis for continued laboratory investigation.

Nevertheless, research findings do not automatically establish therapeutic effectiveness. For example, a large randomized clinical study found that although MK-677 increased serum IGF-1, it did not slow Alzheimer disease progression. Therefore, changes in a biological marker should not automatically be interpreted as evidence of clinical benefit.

Packaging Information

We present the product in a clearly labeled container holding 120 capsules. The packaging identifies ibutamoren as MK-677, communicates 15MG per 1 capsule, displays the stated 99.1% Purity, and identifies the material for research use.

Additionally, the capsule format provides straightforward product identification within our catalog. Consequently, researchers can distinguish this presentation from other MK-677 configurations and from peptide-based research products.

Regulatory Information

We classify the product as Research Use Only and maintain the Not For Human Use designation throughout our product documentation. Accordingly, scientific publications concerning ibutamoren do not constitute regulatory approval for this specific AvigenLab presentation.

Moreover, although researchers have studied MK-677 in controlled human trials, those investigations evaluated specific experimental formulations, populations, and research objectives. Consequently, we focus our documentation on molecular identity, scientific characteristics, research pathways, and product specifications without presenting experimental findings as established therapeutic claims.

Storage and Handling

We recommend following the storage and handling conditions specified in the applicable AvigenLab product documentation. Because capsule stability can depend on formulation, packaging, environmental exposure, and other product-specific variables, we avoid assigning unsupported storage parameters.

Furthermore, researchers should maintain appropriate laboratory handling practices and follow the product-specific documentation associated with the material. Consequently, this approach supports consistent laboratory management without introducing assumptions about conditions that may vary between formulations.

Market Availability

Our capsule presentation provides a defined research configuration containing 15MG of ibutamoren per capsule and 120 capsules per container. The product quantity, stated purity, active compound, capsule format, and Research Use Only classification create clear reference points for laboratory inventory.

Moreover, MK-677 has a substantial research history spanning endocrine signaling, growth hormone physiology, IGF-1 regulation, bone metabolism, and metabolic research. Likewise, controlled studies have examined its effects on pulsatile GH release and downstream IGF-1 responses across different populations and experimental designs.

Product Reference

Our MK-677 Capsules provide a defined ibutamoren research presentation containing 15MG per capsule, 120 capsules, and a stated 99.1% purity. We document the material according to its small-molecule identity, GHS-R activity, GH/IGF-1 research profile, capsule configuration, and Research Use Only classification.

Consequently, the product provides researchers with a clearly identified material for investigating growth hormone secretagogue signaling, pulsatile pituitary release, IGF-1 regulation, endocrine physiology, bone metabolism, and related metabolic mechanisms. Furthermore, the extensive research history surrounding ibutamoren provides a useful foundation for examining how GHS-R activation influences interconnected hormonal pathways under controlled laboratory conditions.